Results from OlympiA’s Phase III trial has shown that its Olaparib (Lynparza) in the adjuvant treatment of patients with germline BRCA1/2 mutations and high-risk early breast cancer reduced the risk of cancer recurrence by 42%.
This means that Olaparib demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo and that the trial has met its primary endpoint.
Olaparib (Lynparza) also demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of distant disease-free survival (DDFS) in the overall trial population. Olaparib (Lynparza) reduced the risk of distant disease recurrence or death by 43%.
Andrew Tutt, OlympiA Steering Committee Chair, Professor of Oncology at The Institute of Cancer Research, said: “We are thrilled that our global academic and industry partnership has been able to help identify a possible new treatment for women with early-stage breast cancer who have mutations in their BRCA1 or BRCA2 genes.
“Olaparib has the potential to be used as a follow-on to all the standard initial breast cancer treatments to reduce the rate of life-threatening recurrence and cancer spread for many patients identified through genetic testing to have mutations in these genes.
“Women with early-stage breast cancer who have inherited BRCA mutations are typically diagnosed at a younger age. Up to now, there has been no treatment that specifically targets these mutations to reduce the risk of recurrence beyond the standard treatments available for early breast cancer.”
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, said: “Olaparib was the first cancer drug in the world to target inherited genetic faults. It is also now the first targeted drug to have been shown to effectively treat patients with inherited mutations and early-stage breast cancer, potentially curing some women of their disease. This is a major breakthrough.
“It’s fantastic that decades of ICR science into identifying cancer’s weaknesses – alongside academic, charity and industry partners in the UK and worldwide – has led to global trials which are now changing the outlook for patients. I am now keen to see this new treatment be approved and made available to patients in the UK and worldwide as fast as possible.”
Lilly Subbotin
This is a syndicated feed from Pharmafile
